Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846657 | 0.88 | HRH4 (0.43) | ACHEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL847981 | 0.88 | ADRB1 (0.47) | ACHEHTR6HRH4ADRB1ALDH1A1 | |
| SCHEMBL846916 | 0.88 | HTR6 (0.51) | ACHEHTR6HRH4HTR3EHTR3B | |
| SCHEMBL848992 | 0.85 | HRH4 (0.65) | ACHEHTR6GABRG2GABRB3GABRA5 | |
| SCHEMBL847193 | 0.84 | ADRB1 (0.50) | HTR6HRH4HTR3EHTR3BADRB1 | |
| SCHEMBL846265 | 0.81 | ACHE (0.65) | ACHEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL1588090 | 0.81 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA3HRH4 | |
| Hydrochloric Acid SCHEMBL1588080 | 0.80 | ACHE (0.64) | ACHEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL846641 | 0.79 | HRH4 (0.53) | ACHEGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1588228 | 0.78 | HRH4 (0.56) | HTR6GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841287-B2 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-23 | — | — | US | claimed |
| EP-2315521-B1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| JP-2011524363-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2315521-A1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2011-05-04 | — | — | EP | claimed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | claimed |
| WO-2009152325-A1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | WO | claimed |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-04 | — | — | US | disclosed |
| US-8841287-B2 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-23 | — | — | US | disclosed |
| US-8841287-B2 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-23 | — | — | US | disclosed |
| EP-2315521-B1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2315521-B1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH1 | ACHE 1337/4885HTR6 161/4885GABRG2 2209/4885 |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | ACHE 1417/4885HTR6 187/4885GABRG2 2424/4885 |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH2 | ACHE 1417/4885HTR6 187/4885GABRG2 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.